The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients’ Survival
Table 1
Correlations between clinical-pathological characteristics of the patients with clear cell renal cell carcinoma (ccRCC) and YAP1 immunoreactivity in the cancer cells (determined by immunohistochemistry).
(a)
Qualitative parameters
Number of patients
YAP1 nuclear immunoreactivity in ccRCC
YAP1 cytoplasmic immunoreactivity in
cells (expressed as scores)
ccRCC cells (expressed as scores)
0-1 (%)
2-3 (%)
value
0 (%)
1-2 (%)
value
Total
54
19 (35.2)
35 (64.8)
41 (75.9)
13 (24.1)
Men
31
11 (35.5)
20 (64.5)
1.0000
24 (77.4)
7 (22.6)
1.0000
Women
23
8 (34.8)
15 (65.2)
17 (73.9)
6 (26.1)
Depth of invasion
T1 + T2
42
13 (31.0)
29 (69.0)
0.3066
30 (71.4)
12 (28.6)
0.2538
T3
12
6 (50.0)
6 (50.0)
11 (91.7)
1 (8.3)
Fuhrman grade
G1 + G2
42
12 (28.6)
30 (71.4)
0.0867
34 (81.0)
8 (19.0)
0.1340
G3
12
7 (58.3)
5 (41.7)
7 (58.3)
5 (41.7)
Distant metastases
M0
47
16 (34.0)
31 (66.0)
0.6866
35 (74.5)
12 (25.5)
1.0000
M1
7
3 (42.9)
4 (57.1)
6 (85.7)
1 (14.3)
(b)
Quantitative parameters
value
value
Age
−0.08
0.5494
−0.01
0.9256
Tumor size
−0.08
0.5544
0.06
0.6581
The scores evaluate percentage cells with YAP1 nuclear immunoreactivity. The scores assess intensity of YAP1 cytoplasmic IHC reactions, both described in Methods. Fisher exact test. Spearman’s correlation.